Signaturefd LLC Trims Stock Holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Signaturefd LLC decreased its holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK) by 8.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 39,487 shares of the company’s stock after selling 3,838 shares during the period. Signaturefd LLC’s holdings in Takeda Pharmaceutical were worth $563,000 at the end of the most recent reporting period.

Other large investors have also recently modified their holdings of the company. XY Capital Ltd increased its holdings in Takeda Pharmaceutical by 432.5% during the 4th quarter. XY Capital Ltd now owns 765,137 shares of the company’s stock worth $10,919,000 after acquiring an additional 621,440 shares during the period. FMR LLC increased its holdings in Takeda Pharmaceutical by 4.7% during the 3rd quarter. FMR LLC now owns 2,593,350 shares of the company’s stock worth $40,119,000 after acquiring an additional 115,947 shares during the period. Brandes Investment Partners LP increased its holdings in Takeda Pharmaceutical by 2.1% during the 3rd quarter. Brandes Investment Partners LP now owns 1,802,036 shares of the company’s stock worth $27,877,000 after acquiring an additional 36,717 shares during the period. Citigroup Inc. increased its holdings in Takeda Pharmaceutical by 5.6% during the 3rd quarter. Citigroup Inc. now owns 57,941 shares of the company’s stock worth $896,000 after acquiring an additional 3,089 shares during the period. Finally, Schonfeld Strategic Advisors LLC bought a new stake in Takeda Pharmaceutical during the 3rd quarter worth approximately $2,105,000. Hedge funds and other institutional investors own 9.17% of the company’s stock.

Takeda Pharmaceutical Stock Performance

Takeda Pharmaceutical stock opened at $13.23 on Thursday. The firm’s 50 day simple moving average is $14.11 and its 200 day simple moving average is $14.22. The company has a current ratio of 1.06, a quick ratio of 0.55 and a debt-to-equity ratio of 0.64. The firm has a market capitalization of $41.87 billion, a PE ratio of 20.05, a price-to-earnings-growth ratio of 3.79 and a beta of 0.53. Takeda Pharmaceutical Company Limited has a 1-year low of $13.11 and a 1-year high of $17.11.

Takeda Pharmaceutical (NYSE:TAK) last issued its quarterly earnings results on Thursday, February 1st. The company reported $0.51 EPS for the quarter. The firm had revenue of $7.52 billion for the quarter. Takeda Pharmaceutical had a net margin of 6.90% and a return on equity of 12.57%. As a group, analysts expect that Takeda Pharmaceutical Company Limited will post 1.5 earnings per share for the current fiscal year.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.